Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study.

Abstract

Eighteen osteoporotic (Z-score at or below 2.5) nonambulatory children with cerebral palsy or a neuromuscular disorder received cyclic intravenous administration of pamidronate. One year after treatment, bone densitometry showed an improvement in all patients: a mean increase of 13% +/- 15% standard deviation (SD) (p < 10(-5)) on the global data, and a mean increase of 27% +/- 15% (p < 10(-5)) on the most significant area for each individual patient. Clinical improvement was found in all patients, with a decrease in pain on manipulation, and no new fractures. No major adverse effects were reported. Cyclic intravenous administration of pamidronate is a useful tool in the treatment of osteoporosis in these children.

• Authors: Nanni Allington, Danielle Vivegnis, Paul Gerard
• Journal: Acta orthopaedica Belgica (Acta Orthop Belg) Vol. 71 Issue 1 Pg. 91-7 (Feb 2005) ISSN: 0001-6462 [Print] Belgium
• PMID: 15792214 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Diphosphonates
• Pamidronate

Topics

• Adolescent
• Anti-Inflammatory Agents (administration & dosage, therapeutic use)
• Cerebral Palsy (complications)
• Child
• Child, Preschool
• Diphosphonates (administration & dosage, therapeutic use)
• Drug Administration Schedule
• Female
• Humans
• Infusions, Intravenous
• Male
• Neuromuscular Diseases (drug therapy, etiology)
• Osteoporosis (drug therapy, etiology)
• Pain (etiology)
• Pamidronate
• Prospective Studies
• Treatment Outcome